The cell surface glycoprotein Trask/CDCP1 is phosphorylated during anchorage loss in epithelial cells where it inhibits integrin clustering, outside-in signaling and cell adhesion. Its role in cancer has been difficult to understand, because of the lack of a discernible pattern in its various alterations in cancer cells. To address this issue, we generated mice lacking Trask function. 
Introduction
Epithelial tumor growth is dependent on a number of cellular processes, one of which is cell adhesion. The relationship between tumor growth and cell adhesion is a complicated one. While the normal epithelium is anchored on an underlying basement membrane, epithelial tumors grow without the requirement for anchorage, and free of the boundaries and restrictions associated with basement membranes. Although the loss of anchorage can have a liberating effect, allowing the often erratic and invasive growth of tumors, the absence of cell adhesion can also have a restrictive effect, disabling signaling pathways important in promoting growth, and removing mechanisms that enable cell migration and invasion. In particular, adhesion signaling through integrin receptors is known to be important in promoting many aspects of tumor growth including proliferation, survival, migration, invasion, and metastasis (1, 2). Integrins not only mediate the migratory functions of tumor cells, but more specifically, cross-talk between integrins and growth factor receptors is thought to be critically important for some tumors (3) (4) (5) , particularly those driven by oncogenic growth factor receptors such as HER2/Neu, and in fact the development of HER2/Neu-driven tumors is considerably delayed or suppressed in mice lacking β1 or β4 integrins (6, 7) . Therefore the relationship between tumorigenesis and cell adhesion is a complex one that likely involves reconciling the tumor promoting and suppressing consequences of integrin engagement and activation. While integrin signaling is generally linked with cell adhesion, their relationship is subject to layers of regulation, and potentially corruptible in tumors seeking freedom from anchorage but persistency in integrin signaling. Here we describe a Src-driven anti-adhesive pathway that negatively regulates integrin signaling and cell growth during anchorage deprivation, conferring a tumor suppressive role and accounting for its observed decrease or loss of expression in some tumors.
Trask (Transmembrane and Associated with Src Kinases, aka CDCP1, SIMA135, gp140) was independently identified by several groups in the recent decade, studying different aspects of cancer biology (8) (9) (10) (11) . The Trask protein is a 140kD transmembrane glycoprotein with a large extracellular domain (ECD) containing CUB domains, and a smaller intracellular domain (ICD) containing five tyrosines and a proline-rich region. Trask is proteolytically cleaved within its ECD by serine proteases including MT-SP1 and is expressed in most cells as a blend of 140kD (uncleaved) and 80kD (cleaved) forms in varying ratios (9, 12) . Trask is widely and abundantly expressed throughout epithelial tissues and specific hematopoietic cells, but its expression is not readily detected in mesenchymal tissues (13, 14) .
In cultured cells we found that Trask undergoes phosphorylation by Src kinases immediately upon the loss of anchorage, and accounts for the majority of cellular phosphotyrosine content in the unanchored state in many cells, and remains phosphorylated until anchorage is restored (13, 15) . When phosphorylated, Trask functions to negatively regulate cell adhesion. This is accompanied by its association with β1-integrin complexes, interfering with integrin clustering, and preventing downstream signaling including the phosphorylation of FAK, establishing pYTrask as a negative regulator of FAK (16) . The anti-adhesive effects of phosphorylated Trask are mediated specifically through the inhibition of integrin clustering without an effect on integrin affinity state (16) . Consistent with its anti-adhesive functions, Trask knockdown confers increased cell adhesiveness, and constitutive Trask phosphorylation blocks cell adhesion (9, 16, 17) . P-Trask interferes with most integrin complexes and adhesion to most matrix ligands, resulting in the inhibition of physical cell-matrix adhesion and consequently the disruption of focal adhesions and focal adhesion signaling through FAK, 130Cas, paxillin, and other focal adhesion proteins (16) . Importantly the phosphorylation of Trask and the phosphorylation of focal adhesion proteins, including FAK, occur in exclusion of eachother, defining a phosphotyrosine switch that underlies cell anchorage state (15, 16 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on December 12, 2012; DOI: 10.1158/0008-5472. CAN-12-2496 In a survey of human epithelial tumors of different types, we found that Trask is phosphorylated in many tumors, usually in a patchy distribution, including pre-invasive, invasive, and metastatic tumors (18) . The phosphorylation of Trask is never seen in normal epithelial tissues except for occasional mitotic or detached cells, consistent with the fully anchored state of the normal epithelium (18) . The observed phosphorylation of Trask in tumors may be either a physiological event reflecting the loss of cell anchorage in regions of tumors, or may be a tumor-promoting pathologic event, perhaps due to the activation of Src kinases.
Experimental studies using human cancer cell lines fail to support a tumor promoting function, and in fact suggest a tumor-suppressing function (19) . Consistent with a tumor-suppressing function, the expression of Trask is reduced or lost in some tumors compared with the normal epithelia and reduced or absent in some cancer cell lines (19) .
In the current study, we set out to more definitively determine the functions of Trask in tumorigenesis. We generated mice lacking Trask function and studied its effects on the development and progression of two oncogene-induced tumors. We found that the loss of Trask significantly accelerates tumorigenesis, confirming a tumor suppressing function. Mechanistic studies on these tumor cells and untransformed epithelial cells reveal that Trask phosphorylation is a mechanism that restricts growth in the unanchored state, at least partly through the inhibition of integrin signaling and its associated cross-talk with growth factor receptors.
Materials and Methods
Targeting vector construction and generation of Trask deficient mice DNA was amplified from mouse 129 isogenic genomic DNA with Pfu Ultra HF polymerase (Invitrogen). 3 DNA fragments were amplified-A,B, and C. Fragment A was amplified with primers ABF3 5' AGGCGCTGGACTCCCAGC and AR1 5' GGCAAGCCAGATTTCAGCCCAA.
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Fragment B was amplified with primers BF1 5' ATCCACGAGGTCCCAGACCATC and ABR1 5'
CCTAAGGCTTGTTCCGCGCGC. Fragment C was amplified with primers CF1 5'CGAGGACGTTCTCCAGGCAGCAC and C20878R 5'CCTTGGCCAGCTTCCAGGTATG. Fragment B is 1,477 bp long and contains exon 1 of Trask and upstream promoter sequences. Loxp sites were engineered at the flanks of fragments B and restriction sites EcoRV, SacI and Swa-1 were introduced immediately adjust to the loxp sites for diagnostic purposes. Fragment A is 3 kb long and serve as 5' arm of the vector, fragment C is 8.5 kb long and serve as a 3' arm. The fragment A,B and C were cloned into pB6 vector. In this vector the Neo cassette is flanked by FRT sites, and the expression of Neo is driven by RNA-pol II promoter. The entire sequence of the targeting vector was determined and found to be correct; and no additional mutations resulting from PCR amplification were found. The targeting construct was linearized with ScaI and electroporated into 129 ES cells. Genomic DNA isolated from 500 G418 resistant ES cell colonies was analyzed by Southern blotting. Several correctly targeted ES cell clones were identified and injected into blastocysts to generate chimeric mice. Chimeras were mated with actin-FLP females on C57/BL6 background (Jackson Lab). Germline transmission and Neo excision were confirmed by Southern analysis. The floxed mice were bred for several generations with normal C57/BL6 mice and later mated with EIIa-cre mice (Jackson lab).
Excision of fragment B and generation of Trask heterozygous mice was confirmed by PCR. These mice were mated several times with normal C57BL/6 mice and the EIIa-cre transgene was bred out. Trask heterozygous mice were bred to generate Trask Wound healing was studied following the experimental induction of a skin wound as has been described previously (21, 22) . Mice were anesthesized, the dorsal skin was shaved, and a thin 7-8mm long full thickness skin cut was made and allowed to heal naturally. At the indicated early or late timepoints after wounding, mice were euthanized, the wounded skin region excised, fixed, embedded in paraffin, and sections stained as indicated. plates at 570 nm.
Matrigel growth assays
Three-dimensional (3D) cultures of MCF-10A cells were prepared as described (23) . Briefly, 24-well culture plate was first coated with growth factor-reduced Matrigel Matrix (BD Biosciences, MA), followed by an overlay of MCF-10A cells (12.5x103/well) in a 5%
Matrigel/media suspension. Cells were grown in a 5% CO2 humidified incubator at 37°C and fed with fully-supplemented MCF-10A media containing 2% Matrigel every 4 days. Cultures were harvested on day 3, 7 and 12 and stained with antibodies against Trask (1:1000), phospho-Trask cloned. The shRNA constructs were transfected into 293T cells along with the appropriate packaging vectors. The resulting lentiviral particles were used to infect MCF10A cells. Cells were selected with G418 (400 μg/ml), and Trask knockdown was confirmed by Western blotting. We then studied differences in growth factor receptor signal transduction in the unanchored state. Our previous work had shown that Trask, when phosphorylated, inhibits integrin clustering and integrin outside-in signaling (9, (15) (16) (17) . Since integrin signaling is known to cross-talk with RTK signaling, it is a logical next hypothesis that the phosphorylation of Trask, through its inhibition of integrin signaling, can inhibit integrin-RTK crosstalk, and negatively impact RTK the unanchored state is mediated through the inhibition of integrin signaling, since this suppression can be made redundant if FAK is directly inhibited, and it can be overcome if integrin β1 signaling is directly activated.
Results

Generation of
The fact that phosphorylated Trask inhibits integrin signaling is entirely consistent with the fact that it also inhibits growth factor signaling, since integrin signaling is well known to crosstalk with and enhance signaling from growth factor receptors (3, 4, 34, 35) . Consistent with this, knockdown of β1 integrin diminishes EGFR signaling activity (36) . How integrins facilitate growth factor receptor signaling is not yet clear. Integrins can be found in association with several growth factor receptors including EGFR and HER2 (37, 38) . Integrins can induce ligandindependent activation of the EGF receptor or can synergistically enhance the growth factor induced activation of downstream MAPK without affecting receptor phosphorylation directly (35, 37) . How integrins enhance growth factor receptor signaling is a subject of continuing debate. One proposed mechanism is that co-clustering with integrins creates increased local receptor density, promoting receptor dimerization and signaling. Another proposed mechanism is that co-localization with integrin clusters brings receptors into a subcellular micro-environment rich in signaling molecules, including various adaptor proteins, or second messengers including Src or FAK (reviewed in (3-5) ). In our study of PyMT-driven tumors, we do not see an 
